It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2022:
Some negative, some positive, but we learned from all!
Feel free to add more & retweet & tag anyone involved
This is not an exhaustive list!
@OncoAlert @DanaFarber
#OnwardFor2023
1/ #ARASENS phase 3 trial shows ⬆️OS with darolutamide in combination with docetaxel and ADT in #mHSPC (vs docetaxel + ADT alone) with similar AE profile, leading to @US_FDA approval.
#MatthewSmith @BertrandTOMBAL @MGHMedicine @NEJM
nejm.org/doi/full/10.10…
2/ In #PCa patients with detectable PSA after prostatectomy, lymph node RT + ADT+ PBRT⬆️freedom from progression compared to ADT+ PBRT and PBRT alone according to #SPPORT trial.
@_APollack @DrHowardSandler @TheLancet
thelancet.com/journals/lance…
3/ Another @US_FDA approved triplet therapy in de novo #mCSPC: abiraterone (+ ADT + docetaxel) improves OS and radiographic PFS compared to SOC±RT in the #PEACE-1 trial with modest⬆️toxicity (mainly HTN).
#Fizazi @AlbertoBossial @GustaveRoussy @TheLancet
thelancet.com/journals/lance…
4/ In 2 #STAMPEDE RCTs: Abiraterone (±enzalutamide) combined with ADT in high risk M0 #PCa⬆️metastasis-free survival, OS, PFS, DSS. Unclear benefit of adding enzalutamide with⬆️toxicity.
@AttardLab @Prof_Nick_James @mattsydes @TheLancet @Silke_Gillessen
thelancet.com/journals/lance…
5/ IL-15 superagonist NAI can induce persistent CR in 71% of BCG-unresponsive #NMIBC with #CIS + 89% avoided cystectomy and 100% DSS at 2 years.
@UroCancerMD @UclaUrology @DrPatSoonShiong @NEJMEvidence
evidence.nejm.org/doi/full/10.10…
6/ In the GETUG-AFU V05 #VESPER trial, neoadjuvant dd-MVAC for M0 #MIBC ⬆️3-year PFS compared to Gem/Cis.
@GETUG_Unicancer @JCO_ASCO
ascopubs.org/doi/full/10.12…
7/ Promising data from 1L enfortumab vedotin + pembrolizumab in cis-ineligible, metastatic #urothelial cancer (EV-103): ORR 73.3%, CRR 15.6% with good tolerability. Median DOR &OS exceeding 2 years. 👀on phase 3 trial.
@DrChrisHoimes @DrRosenbergMSK @JCO_ASCO @OncologyTimes
8/ Data from the #IMmotion010 trial: adjuvant atezolizumab unfortunately did not meet its primary endpoint of improved DFS in #RCC at high risk of recurrence after nephrectomy.
@montypal @UzzoRob #AxelBex @AlbigesL @brian_rini @crisuarez08
thelancet.com/journals/lance…
9/ Promising efficacy of cabozantinib/nivolumab in the treatment of papillary, unclassified and translocation-associated #RCC with a 47.5% ORR (median PFS 12.5 mos and OS 28 mos). Limited response in chromophobe RCC.
@ChungHanLee3 @motzermd @JCO_ASCO
ascopubs.org/doi/full/10.12…
10/ In the phase 2 #SAKK 01/10 trial, single-dose carboplatin followed by involved-node RT in stage II #seminoma showed a favorable efficacy and toxicity profile with 93.7% PFS at 3 years.
@Alex_Papachris @SAKK_ch @TheLancetOncol
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.